Business Wire

Agendia Demonstrates Accessibility and Affordability of MammaPrint® and BluePrint® in Europe at ESMO Breast Cancer 2022

Share

Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced that it will present new data at the European Society for Medical Oncology (ESMO) Breast Cancer Congress 2022 taking place in Berlin, Germany on May 3-5, 2022.

The first of the two poster presentations, entitled Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests [234P], concludes that the next-generation sequencing (NGS) version of MammaPrint and BluePrint[1] is equivalent to the centralized microarray test, as demonstrated by results from various labs globally. This enables a more accurate decentralized solution to breast cancer care fostering worldwide accessibility to more reliable genomic testing.

“The accessibility of breast cancer care is crucial and by validating the interchangeability of the NGS version of MammaPrint and BluePrint compared to the standardized microarray tests, new doors are opened for global physicians who may need to rely on in-country platforms in order to secure the MammaPrint and BluePrint results their patients may require,” said Annuska Glas, Senior Vice President Research and Development and Innovation at Agendia. “MammaPrint is a valuable tool to support treatment planning for breast cancer patients and with the decentralized NGS platform, this can be offered in even more countries. These findings further confirm that MammaPrint and BluePrint can provide the same accurate results through NGS.”

Agendia is expanding novel ways to ensure accessibility of care worldwide by advancing solutions with a decentralized option for testing kits to run on an NGS platform, and innovative modalities such as digital AI pathology. This data presented at ESMO Breast follows an announcement from Agendia earlier this year that it is progressing its Digital MammaPrint artificial intelligence (AI)-powered platform in Brazil to potentially fundamentally change the way breast cancer is treated by providing essential information more quickly and elevating the capabilities of global physicians treating women with breast cancer in their local communities.

A second poster presentation, entitled Budget impact analysis for the Health Care Package by using MammaPrint in Belgium [238P], builds on earlier research from the landmark MINDACT trial and combines this with the results of the interim analysis of the pilot study performed in Belgium (unpublished data). The budget impact model shows that use of MammaPrint yields savings for breast cancer care in Belgium for the Belgian Health Care Package when compared to no gene expression profiling testing. According to the budget impact model, the use of MammaPrint in patients selected according to criteria of the pilot study leads to high savings. If gene expression profiling was performed for all clinical high risk patients, savings would even be higher.

By combining the cost of genomic testing with the savings made due to a net reduction in chemotherapy usage, the annual savings add up to more than €5,800,000, an average savings of €3,900 per patient, compared with standard clinical care of a patient with breast cancer in Belgium. MINDACT has produced previous multi-country health savings analyses, published in the European Journal of Cancer , showing that genomic testing is beneficial as it provides valuable insights that potentially allow patients to avoid the complexity of chemotherapy, passing down significant financial savings to them while also triggering significant cost savings for large health systems around the world.

“Drawing from the impact data used from the pilot study performed in Belgium, we are able to determine new insights that the use of MammaPrint could grant substantial cost savings to women who may not require chemotherapy and could ultimately alleviate some of the burden on Belgium’s health care system as a whole,” said Pino Cusumano, MD, Breast Surgeon, Centre Hospitalier Chrétien, Liège in Belgium. “Data has previously demonstrated that by de-escalating women with Low Risk cases from chemotherapy treatment, outcomes are still as good and women are able to follow a more personalized treatment plan. We believe these data demonstrate that the previous analysis holds for the state of breast cancer care in Belgium in 2022, and that the overall patient benefit extends beyond physical care into financial wellness too.”

Taken together, the two posters presented at ESMO Breast 2022 suggest that regardless of where the patient is located, she is able to receive the same high-quality results with the added benefit of cost-effective treatment planning.

“The studies presented at EMSO 2022 underpin our central efforts at Agendia to ensure our genomic tests are widely accessible and affordable, without compromising scientific integrity or decision-making, to bring the clarity women with breast cancer seek to guide their treatment planning,” said Bastiaan van der Baan, Chief Clinical and Business Development Officer at Agendia. “Through our steadfast commitment to enable global adoption of MammaPrint and BluePrint, we look forward to continuing studies such as these to grow evidence supporting our mission to serve women with breast cancer throughout their treatment journey.”

1MammaPrint and BluePrint next-generation sequencing kits are not yet cleared for sale in the United States by the US Food and Drug Administration; BluePrint has been CE-marked for use in Europe. BluePrint is also commercialized as a Laboratory Developed Test (LDT) and audited under CAP/CLIA in the United States.

About Agendia

Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.

MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of the biology underlying an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.

For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media

Terri Clevenger
ICR Westwicke Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PwC Belgium and BR-AG Collaborate on Agile Platform to Unlock Value Behind Regulatory Reporting18.5.2022 11:03:00 EEST | Press release

As regulatory reporting requirements become more complex and regulators become more demanding on the data quality, financial institutions must deal with time-consuming regulatory reporting processes and manage the associated risks. Tapping into this challenge, PwC Belgium, with the support of technology-collaborator BR-AG, developed Regulatory Reporting Insights, powered by BR-AG’s ATOME Matter and ATOME Particles solutions. “I am excited about the opportunities this improved collaboration with our trusted technology partner BR-AG will bring. This allows financial institutions not only immediate access to an increased level of trust in their regulatory reporting but also to unlock the insights their regulatory reporting contains that was previously only accessible to supervisors.” Jeroen Bockaert, Partner and Product & Services Leader at PwC Belgium “It is truly inspiring that our collaboration with PwC has coined into developing this cutting-edge, data-driven tool. As technology exper

FourKites Hires Supply Chain Veteran in Europe, Underscoring Significant Growth in International Ocean Visibility18.5.2022 11:00:00 EEST | Press release

Philippe Salles has been appointed FourKites’ Vice President of Strategic Solutions (Ocean), bringing a wealth of experience to this booming area of the company’s business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005080/en/ Philippe Salles has been appointed FourKites’ Vice President of Strategic Solutions (Ocean). (Photo: Business Wire) “I’m delighted to be joining FourKites,” says Philippe, who brings experience from CMA CGM, INTTRA and maritime research and consultancy firm Drewry. “Visibility has been ocean shippers’ top priority for decades, and today’s real-time visibility platforms have completely changed the game. In addition to its market-leading machine learning-driven platform, FourKites understands that industry mindset and professionalism are as important as the technology itself. We need to provide shippers with a long-term strategic vision for their supply chain to make them resilient and collabor

Virtual Exhibitions of 23 Museums Lands on the Alipay Platform to Enhance Engagement with Mobile-Savvy Audience18.5.2022 10:46:00 EEST | Press release

On International Museum Day 2022, 4DAGE announced it landed virtual tours and exhibitions of 23 museums, including the historic Henan Museum and Zhejiang Provincial Museum in China and the Hetjens Museum in Germany, through a mini program on Alipay, the leading digital open platform. The collaboration between 4DAGE and Alipay provides China’s mobile-savvy audience an opportunity to better engage with and learn about the museums’ rich histories. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005528/en/ A large bronze mask from China’s “Sanxingdui Ruins” displayed in the Sichuan Museum’s Bronze Age exhibition; from the virtual tour on the Alipay platform (Photo: Business Wire) The mini program “Yunshang Mibao” (translated as “treasure hunting on the cloud”) launched on the Alipay platform provides users an immersive museum-visiting experience at their fingertips. They can appreciate the beauty of cultural relics in 3D an

REPLY – Digital Experience Is Recognised as No. 1 Internet Agency and Company Group for the Fourth Year in a Row by BVDW18.5.2022 10:30:00 EEST | Press release

As done in the previous three years, the Bundesverband Digitale Wirtschaft (BVDW) honours Reply – Digital Experience once again as the top company in their ranking of Internet Agencies for 2022. This recognition shows Reply – Digital Experience’s capability to offer technical solutions in conjuction with creative agency services and the right customer experience strategies. In addition, Reply – Digital Experience saw an increase in sales and their staff in the past financial year as a result of both continuous organic growth and the acquisition of Comwrap, a company headquartered in Frankfurt, specialised in cloud-based digital experience platforms. “To implement a holistic digital experience strategy it is essential to have the interplay of marketing and technology, outstanding creative ideas and a deep understanding of user needs. This involves the use of technology stacks and concepts such as artificial intelligence, virtual and augmented reality, data-driven marketing and conversat

Metanomic Acquires Intoolab, Developers of the First Bayesian Network Artificial Intelligence Engine18.5.2022 10:30:00 EEST | Press release

Today, Metanomic (https://www.metanomic.net/) announces it has acquired Intoolab A.I (https://www.intoolab.com/) , a Bayesian Network Artificial Intelligence company, to expand and to improve data analysis and A.I across video games and Web3. This acquisition augments Metanomic’s current game economy infrastructure that allows developers to build, simulate and run balanced game economies and core gameplay loops in a live, real-time environment. The addition of artificial intelligence helps developers create better experiences through intelligent insight from player behaviour in run-time. As a part of the acquisition the existing solution will be rebranded to Thunderstruck and extend the capabilities of the Metanomic Engine. A more intelligent approach to video game development and Web3 analytics Thunderstruck is based on a new approach to artificial intelligence that is not based on off the shelf machine learning algorithms but a powerful combination of Deep Learning and Dynamic Bayesi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom